Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Khalaf DJ, Aragón IM, Annala M, Lozano R, Taavitsainen S, Lorente D, Finch DL, Romero-Laorden N, Vergidis J, Cendón Y, Oja C, Pacheco MI, Zulfiqar M; PROREPAIR-B investigators; Gleave ME, Wyatt AW, Olmos D, Chi KN, Castro E. Khalaf DJ, et al. Among authors: aragon im. Ann Oncol. 2020 Sep;31(9):1186-1197. doi: 10.1016/j.annonc.2020.06.006. Epub 2020 Jun 20. Ann Oncol. 2020. PMID: 32574722 Free article. Clinical Trial.
Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients.
Oliva L, Lozano R, Llácer C, Aragón I, Pajares BI, Sáez MI, Herrera-Imbroda B, Montesa A, Hernández D, Villatoro R, Otero A, Correa R, Grau G, Peinado P, Pacheco MI, García-Galisteo E, Rueda A, Machuca FJ, Alba E, Márquez-Aragonés A, Olmos D, Castro E. Oliva L, et al. Eur Urol Oncol. 2021 Apr;4(2):315-318. doi: 10.1016/j.euo.2019.06.019. Epub 2019 Jul 13. Eur Urol Oncol. 2021. PMID: 31307957
Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
Lozano R, Salles DC, Sandhu S, Aragón IM, Thorne H, López-Campos F, Rubio-Briones J, Gutierrez-Pecharroman AM, Maldonado L, di Domenico T, Sanz A, Prieto JD, García I, Pacheco MI, Garcés T, Llacer C, Romero-Laorden N, Zambrana F, López-Casas PP, Lorente D, Mateo J, Pritchard CC, Antonarakis ES, Olmos D, Lotan TL, Castro E. Lozano R, et al. Among authors: aragon im. Eur J Cancer. 2021 Apr;147:74-83. doi: 10.1016/j.ejca.2021.01.027. Epub 2021 Feb 21. Eur J Cancer. 2021. PMID: 33626496
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.
Lozano R, Lorente D, Aragon IM, Romero-Laorden N, Nombela P, Mateo J, Reid AHM, Cendón Y, Bianchini D, Llacer C, Sandhu SK, Sharp A, Rescigno P, Garcés T, Pacheco MI, Flohr P, Massard C, López-Casas PP, Castro E, de Bono JS, Olmos D. Lozano R, et al. Among authors: aragon im. Cancers (Basel). 2021 May 12;13(10):2334. doi: 10.3390/cancers13102334. Cancers (Basel). 2021. PMID: 34066080 Free PMC article.
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study.
Conteduca V, Wetterskog D, Castro E, Scarpi E, Romero-Laorden N, Gurioli G, Jayaram A, Lolli C, Schepisi G, Wingate A, Casadei C, Lozano R, Brighi N, Aragón IM, Marin-Aguilera M, Gonzalez-Billalabeitia E, Mellado B, Olmos D, Attard G, De Giorgi U. Conteduca V, et al. Among authors: aragon im. Eur J Cancer. 2021 Jul;152:49-59. doi: 10.1016/j.ejca.2021.04.025. Epub 2021 May 30. Eur J Cancer. 2021. PMID: 34077818
Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
Lozano R, Castro E, Lopez-Campos F, Thorne H, Ramirez-Backhaus M, Aragon IM, Cendón-Florez Y, Gutierrez-Pecharroman A, Salles DC, Romero-Laorden N, Lorente D, González-Peramato P, Calatrava A, Alonso C, Anido U, Arévalo-Lobera S, Balmaña J, Chirivella I, Juan-Fita MJ, Llort G, Y Cajal TR, Almagro E, Alameda D, López-Casas PP, Herrera B, Mateo J, Pritchard CC, Antonarakis ES, Lotan TL, Rubio-Briones J, Sandhu S, Olmos D. Lozano R, et al. Among authors: aragon im. Eur J Cancer. 2023 May;185:105-118. doi: 10.1016/j.ejca.2023.02.022. Epub 2023 Mar 5. Eur J Cancer. 2023. PMID: 36972661
PDE5A Polymorphisms Influence on Sildenafil Treatment Success.
Marchal-Escalona C, Herrera-Imbroda B, Clemente-Postigo M, Alcaide-Torres J, Quiñonero A, Marchal M, Queipo-Ortuño MI, Aragón IM, Martín-Morales A, Lara MF, Cardona F. Marchal-Escalona C, et al. Among authors: aragon im. J Sex Med. 2016 Jul;13(7):1104-10. doi: 10.1016/j.jsxm.2016.04.075. Epub 2016 May 24. J Sex Med. 2016. PMID: 27235284
Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Grávalos C, Sanmartín O, Gúrpide A, España A, Majem M, Suh Oh HJ, Aragón I, Segura S, Beato C, Botella R. Grávalos C, et al. Clin Transl Oncol. 2019 May;21(5):556-571. doi: 10.1007/s12094-018-1953-x. Epub 2018 Oct 3. Clin Transl Oncol. 2019. PMID: 30284232 Free article. Review.
27 results